Related Experiment Video
Updated: Aug 29, 2025
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Histone deacetylase inhibitor use as a radiosensitizer in solid organ malignancies: a systematic review protocol
Jessica Sullivan1, Zhihui Feng2, Paul Fahey3
1School of Medicine, Flinders University, Adelaide, SA, Australia.
Objective:
The objective of this review is to evaluate the efficacy and adverse effects of histone deacetylase inhibitors (HDACi) in combination with radiotherapy for the treatment of solid organ malignancies.
Introduction:
Histone deacetylase inhibitors are a diverse class of drugs that have shown promise as novel anti-cancer therapeutics via epigenetic modification and radiosensitization of neoplastic cells. The aim of HDACi in combination with radiotherapy is to reduce radiation dosage requirements, improve radiotherapy efficacy, and reduce treatment side effects.
Inclusion Criteria:
This review will consider studies utilizing HDACi in conjunction with radiotherapy in adult patients with solid organ malignancy. Sources to be included in this review include experimental and quasi-experimental study designs, analytical studies, and descriptive observational studies.
Methods:
A systematic review of effectiveness will be conducted in accordance with JBI methodology. A detailed search will be conducted via MEDLINE (Ovid), Embase (Ovid), and Scopus. A search of the Cochrane Central Register of Controlled Trials, the International Clinical Trials Registry Platform, and ClinicalTrials.gov will also be performed for relevant trials. Inclusion and exclusion criteria will be utilized to select studies, and papers selected for retrieval will be assessed for methodological validity using the JBI critical appraisal instruments. Evidence will be extracted from eligible studies and summarized using quantitative methods, where possible, including meta-analysis and assessment of heterogeneity. Where statistical pooling is not possible, the findings will be presented in diagrammatic or tabular form accompanied by a narrative summary.
Systematic Review Registration Number:
PROSPERO CRD42021293005.
Insights
This review evaluates histone deacetylase inhibitors (HDACi) combined with radiotherapy for solid organ cancers. The goal is to assess if this combination improves cancer treatment efficacy and reduces side effects.
Area of Science:
- Oncology
- Pharmacology
- Radiotherapy
Background:
- Histone deacetylase inhibitors (HDACi) are a class of drugs targeting epigenetic modification.
- HDACi show potential as anti-cancer therapeutics by radiosensitizing neoplastic cells.
- Combining HDACi with radiotherapy aims to lower radiation doses and improve treatment outcomes.
Purpose of the Study:
- To evaluate the efficacy of histone deacetylase inhibitors (HDACi) in combination with radiotherapy.
- To assess the adverse effects of this combined treatment modality.
- To determine the impact on solid organ malignancies.
Main Methods:
- Systematic review of effectiveness following JBI methodology.
- Comprehensive search of databases including MEDLINE, Embase, Scopus, and clinical trial registries.
- Inclusion of experimental, quasi-experimental, analytical, and descriptive observational studies in adult patients.
Main Results:
- Evidence extraction and quantitative synthesis, including meta-analysis where feasible.
- Assessment of study heterogeneity.
- Presentation of findings in tabular or diagrammatic form with narrative summary if statistical pooling is not possible.
Conclusions:
- The review will synthesize current evidence on HDACi and radiotherapy for solid organ malignancies.
- Findings will inform clinical practice regarding the combined use of HDACi and radiotherapy.
- This systematic review aims to clarify the role of HDACi in enhancing radiotherapy efficacy and safety.
More Related Videos
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
09:05Generation and Quantitative Analysis of Pulsed Low Frequency Ultrasound to Determine the Sonic Sensitivity of Untreated and Treated Neoplastic Cells
Published on: July 22, 2015
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...